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Background: High-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and
triglyceride (TG) levels are influenced by both genes and the environment. Genome-wide association studies
(GWAS) have identified ~100 common genetic variants associated with HDL-C, LDL-C, and/or TG levels, mostly in
populations of European descent, but little is known about the modifiers of these associations. Here, we
investigated whether GWAS-identified SNPs for lipid traits exhibited heterogeneity by sex in the Population
Architecture using Genomics and Epidemiology (PAGE) study.
Results: A sex-stratified meta-analysis was performed for 49 GWAS-identified SNPs for fasting HDL-C, LDL-C, and ln
(TG) levels among adults self-identified as European American (25,013). Heterogeneity by sex was established when
phet < 0.001. There was evidence for heterogeneity by sex for two SNPs for ln(TG) in the APOA1/C3/A4/A5/BUD13
gene cluster: rs28927680 (phet = 7.4x10
-7) and rs3135506 (phet = 4.3x10
-4), one SNP in PLTP for HDL levels (rs7679;
phet = 9.9x10
-4), and one in HMGCR for LDL levels (rs12654264; phet = 3.1x10
-5). We replicated heterogeneity by sex in
five of seventeen loci previously reported by genome-wide studies (binomial p = 0.0009). We also present results for
other racial/ethnic groups in the supplementary materials, to provide a resource for future meta-analyses.
Conclusions: We provide further evidence for sex-specific effects of SNPs in the APOA1/C3/A4/A5/BUD13 gene cluster,
PLTP, and HMGCR on fasting triglyceride levels in European Americans from the PAGE study. Our findings emphasize the
need for considering context-specific effects when interpreting genetic associations emerging from GWAS, and also
highlight the difficulties in replicating interaction effects across studies and across racial/ethnic groups.
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The successes of genome-wide association studies
(GWAS) in mapping over 100 loci associated with high-
density lipoprotein cholesterol (HDL-C), low-density
lipoprotein cholesterol (LDL-C), and triglyceride (TG)
levels have advanced our understanding of genomic in-
fluences on common diseases [1-11]. However, the
translation of such knowledge into clinical and public
health applications requires exploration of the epidemio-
logical architecture of these variants. Epidemiologic
architecture describes the features of genetic associations
in a population-based context that could act as modifiers
of these associations [12]. Typical features include
demographics (sex, age, and genetic ancestry) and vari-
ous environmental exposures. The epidemiologic archi-
tecture of GWAS-identified genetic variants has largely
been unexplored.
Differences in lipid profiles and metabolism between
men and women have been well documented [13,14]. Pre-
menopausal women have more favorable plasma lipid pro-
files than men, with lower levels of TG, total cholesterol
(TC), and LDL-C, and higher of HDL-C [15-18]. Men and
women also differ in lipoprotein particle concentration,
subclass distribution, and sizes. For example, women have
a larger average size of LDL and HDL particles than men
[19,20]. Sex differences in lipid metabolism and lipopro-
tein kinetics are also well described [21]. However, the
molecular basis of sexual dimorphism in lipid metabolism
is poorly understood. Differences in sex hormones, body
size and composition, and underlying genetic factors may
each partially be implicated [17,18,22].
Sex-specific heritabilities of lipid traits have been pre-
viously reported [23,24]. Despite considerable advances
in the identification of genetic variants influencing
plasma lipid levels, few studies have examined the role
of sex as a potential modifier of the effects of genetic
variation on lipids. Sex-specific genetic associations may
provide valuable insight into the factors responsible for
the recognized sexual dimorphism in the plasma lipid
profile, a major risk factor for cardiovascular disease,
and, thus, may have significant public health and clinical
relevance [25]. Accounting for the modifying effects of
sex in genetic associations of lipid traits may also help in
replication of results across studies and in generalization
of findings across different populations.
We, therefore, investigated the sex-specific associa-
tions of 49 GWAS-identified SNPs with three common
lipid traits (LDL-C, HDL-C, and TG) in the diverse co-
horts of the Population Architecture using Genomics
and Epidemiology (PAGE) study, established in 2008 by
the National Human Genome Research Institute to in-
vestigate and characterize the epidemiologic architecture
of GWAS-identified variants in diverse racial/ethnic
groups [12]. We find significant heterogeneity by sex inthree previously reported loci, and replicated heterogen-
eity by sex at nominal levels in three additional loci.Results
Study populations
Table 1 illustrates the diversity of the PAGE study by ra-
cial/ethnic group or population, sex, age range, and years
of data collection. There were 25,013 European Americans,
10,643 African Americans, 6,134 American Indians, 3,422
Mexican Americans/Hispanics, 827 Japanese/East Asians,
and 200 Pacific Islanders/Native Hawaiians. Overall, there
were more women (29,330) than men (16,909). Results are
presented for the four largest racial/ethnic groups to main-
tain adequate sample sizes when investigating interactions.
HDL-C, LDL-C, and ln(TG), stratified by sex, and racial/
ethnic group, are shown in Table 2. Lipid levels are further
stratified by cohort in Additional file 1: Table S1. Females
had higher mean HDL-C levels than males across all four
racial/ethnic groups, though LDL-C and ln(TG) profiles
were similar (Table 2).Heterogeneity by sex in PAGE European Americans
Four SNPs across three different loci showed significant
evidence of heterogeneity by sex at our established level of
significance (phet < 0.001) in EAs, in HDL-C, ln(TG), and
LDL-C levels (Table 3). The complete sex-stratified results
for all 49 SNPs in the four largest PAGE racial/ethnic
groups are shown in Additional file 1: Tables S2–S4.
In the APOA1/C3/A4/A5/BUD13 gene cluster, the C allele
of rs28927680 was associated with increased ln(TG), but
more strongly in males than females (Phet = 7.4×10
-7). This
SNP is in linkage disequilibrium with the other APOA1/C3/
A4/A5 SNP presented in Table 3, rs3135506 (r2 = 0.83). In
PLTP, rs7679 was strongly associated with HDL-C levels in
females (p = 6.3×10-6), but there was no effect in males (p =
0.73) (phet = 9.9×10
-4). In HMGCR, rs12654264 had a stron-
ger effect on LDL-C levels in males (p = 8.3×10-14) than in
females (p = 6.0×10-3) (phet = 3.1×10
-5).
The only group with adequate power to detect interac-
tions was EAs, and then only with SNPs that have larger
allele frequencies and interaction effect sizes. For SNPs
with a minor allele frequency of 0.15, the minimum de-
tectable interaction effects with 80% power for HDL-C
were 1.1 mg/dL in EAs, 1.8 mg/dL in AAs, 2.2 mg/dL in
AIs, and 2.9 mg/dL in the Mexican population. These
numbers represent the minimum detectable difference,
comparing the effect size of a SNP on HDL-C levels in
males vs. the effect size in females. The mean interaction
effect for EAs across all SNPs for HDL-C was 0.35 mg/dL;
only two SNPs with MAF > 0.15 had an interaction effect
greater than 1.1 mg/dL (Additional file 1: Table S4).
Additional file 1: Figure S1 shows the sample sizes re-
quired for minimum detectable interactions observable (in
Table 1 Characteristics of PAGE study populations
EAGLE* MEC WHI CALiCo
ARIC CARDIA CHS SHS
Type of Study Cross-sectional Nested Case Control Cohort and Clinical Trials Longitudinal Longitudinal Longitudinal Longitudinal
Focus of Cohort N/A Cancer Women’s Health Cardiovascular
Disease
Cardiovascular
Disease
Cardiovascular
Disease
Cardiovascular
Disease
Years Collected 1991-1994, 1999-2002 1993-1996 1993-1998 1987-2007 1986-2006 1989-1999 1988-present
Median Age 43 67 63 54 25 73 47
Age Range 18-90 48-86 50-79 44-66 18-35 64-96 14-93
% Women 54 36 100 57 56 62 59.3
Sample sizes:
European Americans 3,909† 317 4,688 11,178 2,134 2,787 –
African Americans 1,896 552 1,840 3,770 2,035 550 –
American Indians – – 113 – – – 6,021
Mexican Americans 2,361 299 762 – – – –
*Abbreviations: Epidemiologic Architecture for Genes Linked to Environment (EAGLE); Multiethnic Cohort (MEC); Women’s Health Initiative (WHI); Causal Variants
Across the Life Course (CALiCo); Atherosclerosis Risk in Communities (ARIC); Coronary Artery Risk Development in Young Adults (CARDIA); Cardiovascular Health
Study (CHS); Strong Heart Study (SHS).
†The numbers shown are the maximum for any of the three phenotypes (LDL, HDL, or lnTG).
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frequencies.
Although not sufficiently powered to detect inter-
action in the other ethnic groups we include these re-
sults in the supplementary materials as a resource to
build sample sizes large enough across these minority
groups through meta-analysis. LDLR SNP rs6511720
met the criterion for heterogeneity in the Mexican
American/Hispanic group (phet = 3.5×10
-4), with a sig-
nificant positive effect on ln(TG) levels in males and a
significant negative effect in females (Additional file 1:
Table S2). The same trend was also observed for
American Indians for this SNP. In HNF4A, rs1800961
had a significant negative effect on HDL-C levels in AA
males but no effect in AA females (phet = 2.6×10
-4),
although the minor allele frequency was only 0.01
(Additional file 1: Table S4). No other SNPs met the
pre-specified criterion for declaring significant hetero-
geneity by sex for any of the three phenotypes in these
racial/ethnic groups.Table 2 Mean lipid levels by sex and racial/ethnic group in th
Lipid Sex Mean lipid
European Americans African Amer
HDL-C Male 44.2 (42.6, 49.7) 51.6 (50.4, 53.4
Female 57.5 (56.3, 64.3) 57.4 (55.1, 64.2
LDL-C Male 131.4 (111.8, 140.1) 124.5 (108.8, 13
Female 130.7 (105.7, 135.5) 128.6 (111.7, 13
lnTG Male 4.80 (4.32, 4.88) 4.48 (4.11, 4.63
Female 4.79 (4.14, 4.98) 4.51 (4.05, 4.70
*Ranges are provided for cohort means, not for individuals. For example, for Europe
to 49.7 (in MEC). See Additional file 1: Table S1 for detailed information by cohort.Replication of previously published reports of
heterogeneity
Seventeen SNPs in our dataset have shown evidence of
heterogeneity by sex for LDL-C, HDL-C, or TG in previ-
ously published genome-wide studies, or are in linkage
disequilibrium (R2 > 0.2) with previously reported SNPs
(Table 4). Heterogeneity by sex was replicated for PLTP
and the BUD13 locus at our established level of signifi-
cance (p < 0.001), as also shown in Table 3. (Note, het-
erogeneity by sex has been previously reported in
HMGCR for total cholesterol levels, but we did not have
results for total cholesterol and therefore this locus did
not meet the criteria for inclusion in Table 4). Hetero-
geneity by sex was replicated for three additional loci
(LPL, TRIB1, and GCKR) at a nominal p < 0.05 level. The
binomial p-value for replicating 5 of 17 findings at p <
0.05 is 0.0009. For all five of these loci, the direction of
the interaction was consistent with the previous report
[26]. The effect was larger in males for four of the five
loci, and stronger in females for one locus.e PAGE study
levels (in mg/dL) and cohort ranges*
icans Mexican Americans/Hispanics American Indians
) 45.4 (44.9, 48.4) 43.0 (41.9, 43.9)
) 52.7 (51.7, 56.0) 48.0 (45.3, 53.1)
7.8) 124.0 (118.1, 125.0) 109.4 (97.8, 116.6)
8.0) 121.4 (117.0, 128.9) 108.4 (99.3, 126.1)
) 4.90 (4.89, 4.95) 4.79 (4.71, 4.85)
) 4.94 (4.88, 5.09) 4.82 (4.79, 4.96)
an American males, the cohorts’ mean HDL values ranged from 42.6 (in ARIC)
Table 3 Loci with evidence of heterogeneity by sex (Phet < 0.001) in PAGE European Americans
Gene SNP Coded
Allele
Pheno-
type
Males Females
P†comb P
‡
diff
§PhetCAF β (SE) P N CAF β (SE) P N
APOA5/BUD13 cluster rs28927680 C ln(TG) 0.07 0.13 (0.02) 5.4E-17 9136 0.07 0.04 (0.01) 3.77E-04 15137 2.3E-14 9.8E-19 7.4E-07
rs3135506 C ln(TG) 0.06 0.16 (0.02) 1.9E-22 8173 0.06 0.09 (0.01) 1.16E-13 9588 8.4E-32 2.3E-33 4.3E-04
PLTP rs7679 T HDL 0.82 0.10 (0.30) 7.3E-01 5439 0.82 1.68 (0.37) 6.27E-06 6089 1.9E-03 3.5E-05 9.9E-04
HMGCR rs12654264 A LDL 0.62 −4.03 (0.54) 8.3E-14 8088 0.62 −1.17 (0.42) 5.98E-03 12424 1.2E-11 1.7E-14 3.1E-05
*Abbreviations: CAF = coded allele frequency; SE = standard error.
†P-value for SNP-phenotype association in the sex-combined meta-analysis, not allowing for heterogeneity by sex.
‡P-value for SNP-phenotype association in the sex-combined meta-analysis, allowing for different effects by sex.
§P-value for heterogeneity by sex.
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required in order to have 80% power to replicate the
previously reported interaction effect, given the allele
frequency in PAGE and the R2 between the PAGE SNP
and the prior SNP (Table 4). Notably, the required sam-
ple sizes to achieve 80% power were >100,000 for 14 of
the 17 SNPs. For the one SNP where we were adequately
powered to detect interaction (rs10401969 in CILP2), we
observed a stronger effect in males than in females, con-
sistent with the previous report, though the directions of
effect for the T allele appear to be opposite (positive for
both males and females in the prior study, but negative
for both sexes in ours) [8].Discussion
We have examined the sex-specific effects of 49 selected
SNPs on circulating lipids in 46,349 PAGE study partici-
pants from four racial/ethnic groups. Four SNPs in three
loci (HMGCR, PLTP, and APOA5/BUD13) displayed evi-
dence of sex-SNP interactions for fasting lipid levels
according to our pre-specified significance criterion.
Heterogeneity by sex for lipid levels had been previously
reported in other contexts for each of these loci. We
were also able to replicate previously reported hetero-
geneity by sex at three additional loci (TRIB1, LPL, and
GCKR) at nominal levels of significance, despite being
underpowered to detect these interactions, with required
sample sizes exceeding 100,000 in most cases.
Although we also analyzed these data in African
Americans, American Indians, and Mexican American/
Hispanics, we were underpowered to detect interactions
in these groups, though two associations reached statis-
tical significance. Sex-SNP interactions that are consist-
ent across populations likely reflect the effects of the
biological differences between men and women that are
expected to be shared by all population groups. How-
ever, differences in power and LD patterns between
population groups, as well as possible unrecognized ra-
cial/ethnic-specific effects on the sexual dimorphism of
lipid levels may have obscured consistent sex-SNP inter-
actions effects across population groups.Two published GWAS and one gene-centric genome-
wide study have tested for heterogeneity by sex for lipid
levels among their associated loci. Three of 22 lipid-
associated loci (HMGCR, LPL, and NCAN) exhibited
evidence of heterogeneity by sex for either TC or HDL-
C levels in a meta-analysis of >20,000 European individ-
uals, though the criterion used for heterogeneity was not
stated explicitly [1]. Four of 95 associated loci (LPL, CILP2,
APOE, and ZNF664) exhibited evidence of heterogeneity
by sex (Phet < 0.0005) for TC, TG, LDL-C, or HDL-C levels
in a recent meta-analysis of >100,000 individuals of
European ancestry, and seven additional loci were
genome-wide significant in one sex but not the other [8].
In the most recent gene-centric genome-wide study, 44
SNPs of ~50,000 were defined as exhibiting heterogeneity
by sex for TC, TG, HDL-C, or LDL-C [26].
Association data for seventeen of the previously
reported loci from GWAS were available in PAGE. We
attempted to replicate the prior findings for TG, HDL and
LDL if we had a SNP in linkage disequilibrium (R2 > 0.20)
with the reported SNP. We did not have association re-
sults for total cholesterol, and therefore did not attempt to
replicate those findings from any of the prior studies. Five
of the previously reported GWAS-identified sex-specific
effects consistently replicated in the PAGE study for the
same phenotype. There was some overlap in the sample
between PAGE and the other meta-analyses; for example
PAGE cohorts also analyzed in the gene-centric meta-
analysis by Asselbergs et al. include ARIC, WHI, CAR-
DIA, and CHS [26].
Power impacted our ability to detect significant sex ef-
fects, with sample sizes necessary for 80% power exceed-
ing 100,000 in 14 of the 17 loci. Although we did not have
large sample sizes, we did have the advantage of having
previously unreported data for these loci in additional ra-
cial/ethnic groups. Of these five loci that were replicated
in EAs, the four TG loci (APO gene cluster, GCKR, LPL,
and TRIB1) had consistent directions of interaction in
Mexican Americans/Hispanics, though effects were less
consistent for the other racial/ethnic groups (Additional
file 1: Table S2). It would be worthwhile to continue this
area of investigation to determine whether interaction
Table 4 Replication of previously reported heterogeneity by sex in PAGE
Prior study PAGE
Gene Trait SNP CA CAF Beta (SE), male Beta (SE), female PAGE SNP §R2 CA CAF Required sample
size@ for 80% power
to detect interaction
Beta (SE), male Beta (SE), female Phet Sex with stronger
absolute effect
(prior, PAGE)
Significant heterogeneity in PAGE (phet < 0.05)
BUD13 TG rs11820589 A 0.05 0.131 (0.009) 0.091 (0.008) rs3135506 0.79 C 0.06 215,337 0.16 (0.02) 0.09 (0.01) 4.3E-4 MM
GCKR TG rs1260326 T 0.41 0.064 (0.005) 0.050 (0.004) rs1260326 - T 0.42 370,777 0.072 (0.009) 0.046 (0.006) 0.013 MM
LPL TG rs13702 T 0.70 0.070 (0.005) 0.047 (0.004) rs328 0.39 C 0.90 389,318 −0.110 (0.014) −0.069 (0.009) 0.013 MM
PLTP HDL rs6065904 A 0.22 −0.008 (0.003) −0.031 (0.004) rs7679 0.86 T 0.82 242,184 0.10 (0.30) 1.68 (0.37) 9.9E-4 FF
TRIB1 TG rs2954033 A 0.30 0.050 (0.005) 0.022 (0.004) rs2954029 0.36 A 0.54 137,339 −0.059 (0.010) −0.031 (0.006) 0.015 MM
No significant heterogeneity in PAGE (phet > 0.05)
APOB TG rs11902417 A 0.23 −0.038 (0.006) −0.024 (0.005) rs693 0.27 T 0.49 >1,000,000 −0.025 (0.009) −0.014 (0.007) 0.32 MM
APOB LDL rs531819 T 0.15 −0.092 (0.012) −0.128 (0.012) rs562338 0.70 T 0.19 126,763 −5.32 (0.73) −5.96 (0.66) 0.51 FF
CETP HDL rs7499892 T 0.17 −0.074 (0.004) −0.091 (0.005) rs1864163 0.57 A 0.24 525,658 −2.57 (1.55) −1.16 (2.68) 0.65 FM
CILP2‡ LDL rs10401969 T 0.07 0.15 (0.02) 0.03 (0.01) rs16996148 1.0 T 0.08 18,530 −3.44 (0.96) −2.11 (0.76) 0.28 MM
FADS1 HDL rs174548 C 0.70 0.015 (0.003) 0.024 (0.004) rs174547 0.80 T 0.66 986,476 0.82 (0.22) 0.60 (0.20) 0.47 FM
GALNT2 HDL rs2296065 A 0.85 0.015 (0.004) 0.030 (0.005) rs2144300 0.26 T 0.60 >1,000,000 0.21 (0.19) 0.63 (0.17) 0.091 FF
GALNT2 TG rs2296065 A 0.85 −0.015 (0.007) −0.027 (0.005) rs2144300 0.26 T 0.60 >1,000,000 0.015 (0.008) 0.019 (0.006) 0.73 FF
LIPC HDL rs2070895 A 0.22 0.033 (0.003) 0.051 (0.004) rs261332 0.91 A 0.20 375,405 1.77 (0.32) 1.72 (0.42) 0.96 FM
LIPG HDL rs2156552 A 0.16 −0.023 (0.004) −0.032 (0.005) rs2156552 - T 0.17 >1,000,000 −0.38 (0.24) −0.56 (0.24) 0.60 FF
LPL HDL rs10096633 A 0.40 0.014 (0.032) 0.079 (0.011) rs328 0.87 G 0.10 53,495 1.76 (0.31) 1.93 (0.28) 0.68 FF
LPL‡ HDL rs12678919 A 0.12 −0.20 (0.01) −0.13 (0.01) rs328 1.0 G 0.10 40,123 1.76 (0.31) 1.93 (0.28) 0.68 MF
LPL† HDL rs2083637 G 0.26 0.149 0.079 rs328 0.43 G 0.10 93,909 1.76 (0.31) 1.93 (0.28) 0.68 MF
PLTP TG rs6073952 A 0.19 0.009 (0.006) 0.030 (0.005) rs7679 1.0 T 0.82 247885 0.013 (0.013) 0.009 (0.011) 0.82 FM
TRIB1 LDL rs17321515 A 0.52 0.022 (0.008) 0.045 (0.009) rs2954029 0.97 A 0.54 63691 1.98 (0.67) 2.16 (0.49) 0.83 FF
*Abbreviations: CA = coding allele; CAF = coding allele frequency; SE = standard error; Phet = heterogeneity by sex p-value.
All prior SNPs shown are from Asselbergs et al. (2012), except for the three noted.
†Aulchenko, Ripatti et al., 2009. Standard errors were not reported for sex-specific effects.
‡Teslovich, Musunuru, et al., 2010. Effect sizes were reported for standardized residuals and therefore are not directly comparable to the PAGE results.
§LD was calculated using 1000 Genomes Pilot 1 data (CEU population).
%Criteria for replication: phet < 0.05 in PAGE and consistent direction of interaction effect (e.g., stronger effects in females in both PAGE and prior study).
@Sample size calculations for gene-environment interactions done on Quanto, assuming the CAF from PAGE and the difference in βf-βm from the prior study. Calculated sample sizes were then divided by R
2 (the LD
between the PAGE SNP and the prior SNP) to arrive at the final required sample size for 80% power, shown in the table.
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racial/ethnic groups, as this evidence points to genera-
lization in MA/H but not the other groups.
Several candidate gene studies have reported heterogen-
eity by sex for rs3135506 [27-30], and a nearby SNP was
recently reported with heterogeneity by sex (rs11820589;
R2 = 0.65 with rs28927680) [26]. In PAGE, this variant was
associated with ln(TG) in all four major populations tested
in the sex-combined meta-analysis [12]. Significant evi-
dence of heterogeneity by sex in PAGE was observed for
European Americans and Mexican Americans/Hispanics.
In these two groups, significantly stronger effects in males
compared with females were observed. A British study
reported results consistent with the PAGE study [30]. A
Turkish study reported significant associations between
triglyceride levels and rs3135506, with a stronger associ-
ation in women [29]. Sex-differentiated effects have also
been reported for triglyceride levels and rs3135506 in a
Brazilian population of European descent, again with the
female effects stronger than male effects [27]. Klos et al.
[28] had previously reported heterogeneity by sex for this
SNP in the CARDIA study (data not included in the
present study), where it was significantly associated with
plasma TG levels in African-American females, but not
males. There is also evidence that serum ApoA5 levels are
correlated with triglyceride levels and HDL-C levels more
strongly in females than in males [31]. Different results
observed across different cohorts that represent various
genetic ancestries highlight the complexities in replicating
and ultimately interpreting sex differences in genetic asso-
ciation studies.
Aulchenko et al. [1] reported heterogeneity by sex for
HMGCR rs3846662 for total cholesterol. We did not test
for heterogeneity by sex for total cholesterol in the PAGE
study. We did note, however, that HMGCR rs12654264,
which is in strong LD with previously reported rs3846662
(r2 = 0.87), displayed significant heterogeneity by sex for
LDL-C (Phet = 3.1×10
-5), a trait highly correlated with total
cholesterol. In the PAGE study, however, the genetic effect
was greater in males (β = −4.03) compared with females
(β = −1.11), which does not replicate the findings of
Aulchenko et al. [1]. The product of the HMGCR gene (3-
hydroxy-3-methylglutaryl-CoA reductase) is the rate-
limiting enzyme of the cholesterol biosynthesis pathway
and the target of statins, a class of drugs widely used for
the treatment of high cholesterol. Sequence variants of
this gene have been associated with variation in response
to statin therapy [32]. Among patients with asymptomatic
plaques in the carotid artery from the Malmö Diet and
Cancer-Cardiovascular Cohort, rs12654264 was associated
with reduction in LDL-C levels in response to fluvastatin
treatment in men but not women [33].
Heterogeneity by sex for HDL-C levels for PLTP
(phospholipid transfer protein) has been previouslyreported, with consistent findings [26]. Studies have pro-
vided evidence that PLTP activity may affect HDL par-
ticle size [34]. In PAGE, the major allele of rs7679 was
associated with higher HDL-C levels in women only.
The locus with the most consistent evidence for het-
erogeneity by sex across the studies is LPL, or lipopro-
tein lipase. Different SNPs in this gene exhibited
heterogeneity by sex for HDL levels in two prior studies,
with a larger effect in males [1,8]. In PAGE and in
Asselbergs et al., LPL exhibited heterogeneity by sex for
TG levels, also with a stronger effect in males [26]. LPL
(lipoprotein lipase) is the rate-limiting enzyme for hy-
drolysis of triglycerides in lipoproteins. Polymorphisms
and mutations in LPL have been associated with lipid
metabolism disorders. Hormone levels have been shown
to affect regulation of LPL, including thyroid hormone,
estrogen, and testosterone [35].
Strengths and limitations
The diversity of the PAGE study potentially enabled us
to examine potential sex-effects across populations,
though we were underpowered to detect interactions in
three of the four racial/ethnic groups. Physiological, ana-
tomical, or even behavioral differences between men and
women that may modify the effects of SNPs on lipid me-
tabolism are expected to be largely shared across racial/
ethnic groups. Hence, the consistent effects across ra-
cial/ethnic groups described above provide added sup-
port to the findings reported here.
Some limitations must be acknowledged, including
sample size. Power to detect interaction effects typically
requires substantially larger samples than those for main
effects [36,37]. Sample size was greatest for European-
Americans and, not unexpectedly, most evidence of
sex-specific effects in this study was observed in this
population. The required sample sizes to detect inter-
action for these loci (generally exceeding 100,000, and
sometimes exceeding 1,000,000) should alert other in-
vestigators to the difficulty of replicating interaction
effects.
The PAGE study cohorts differ in many aspects, includ-
ing study design, period of collection, demographics and
cardiovascular and metabolic risk factors of the participants.
These differences may have further reduced our power to
detect significant modifying effects of sex on SNPs-lipids
associations. Indeed, sex differences not only represent bio-
logical differences between men and women but also en-
compass or are confounded by social and behavioral
differences between the two sexes. Difficulties in assessing
and accounting for such factors in a consistent and accurate
manner across the multiple cohorts likely further reduced
our power to detect interaction with genetic factors.
This difficulty of replicating heterogeneity by sex is
compounded by the nature of the tested SNPs, which
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themselves causal. Differences in LD patterns across
studies and racial/ethnic groups may have hampered our
ability to detect consistent sex modification effects in
some population groups.
Claims of modification by sex have been difficult to
replicate for most complex diseases and many studies
lack the proper documentation for the claim of signifi-
cant sex-effects [38]. In this study, we note that the three
loci which met our a priori criterion for significant inter-
action had been previously reported to display hetero-
geneity by sex, suggesting that the initial reports for
these loci were not attributable to type I error.
Differences in sex hormone levels have been hypothe-
sized to play a role in the sexual dimorphism of circulat-
ing lipids. In this study, we did not examine whether
menopausal status modified the association of these
SNPs with lipid levels in women. Future such investiga-
tions may help shed light on the biological basis of the
sex-specific associations reported here.
Conclusions
Using a rigorous methodology and the diverse popula-
tions of the PAGE study, we have confirmed previously
reported heterogeneity by sex for lipid levels for six loci.
Genotype-sex interactions may represent an important
source of genetic variation that may contribute to the
“missing heritability” of complex traits. Although chal-
lenging, assessment of sex-specific associations should
be more widely considered in order to characterize the
genetic architecture of complex, sexually dimorphic
traits, such as lipids.
Methods
Study populations and phenotypes
The study population included 46,239 individuals from co-
horts which are part of the PAGE study, a collaborative
program across four large population-based studies or
consortia, including EAGLE (Epidemiologic Architecture
for Genes Linked to Environment), based on three
National Health and Nutrition Examination Surveys
(NHANES) [39]; the Multiethnic Cohort (MEC) [40]; the
Women’s Health Initiative (WHI) [41]; and the Causal var-
iants Across the Life Course (CALiCo) consortium, which
encompasses five studies: Atherosclerosis Risk in Commu-
nities (ARIC) [42], Coronary Artery Risk in Young Adults
(CARDIA) [43], the Cardiovascular Health Study (CHS)
[44], Strong Heart Family Study (SHFS) and Strong Heart
Study (SHS) [45]. Details about the design of the PAGE
study have been previously published [12]. All participants
were consented and all studies were approved by Institu-
tional Review Boards at their respective sites.
Serum HDL-C, triglycerides, and total cholesterol were
measured using standard enzymatic methods. LDL-Cwas calculated using the Friedewald equation, with miss-
ing values assigned for samples with triglyceride levels
greater than 400 mg/dl. For PAGE cohorts with longitu-
dinal data, measurements from the baseline examination
were used in the analyses.
The PAGE study participants who were less than 18
years of age and those fasting for less than 8 hours prior
to the blood draw were excluded from analyses. Partici-
pants with triglycerides values >1,000 mg/dl were ex-
cluded from analyses of that trait. The distribution of
triglyceride levels was skewed and thus values were nat-
ural log transformed prior to analysis. A further descrip-
tion of the study design, methods of data collection and
participants’ characteristics for each of the cohorts have
been presented elsewhere [46].
SNP selection and genotyping
Detailed methods of SNP selection and genotyping have
been described previously [12]. Briefly, a total of 52
SNPs previously associated with HDL-C, LDL-C, and/or
triglycerides in published candidate gene and genome-
wide association studies (through 2008) were targeted
for genotyping in two or more PAGE cohorts. Of these,
three (CETP rs1800775, APOE rs429358, and APOE
rs7412) failed at all PAGE study sites that attempted
genotyping; therefore, a total of 49 SNPs were included
in this analysis. Genotyping was performed by each of
the four PAGE studies using commercially available
genotyping arrays (Affymetrix 6.0, Illumina 370CNV
BeadChip), custom mid- and low-throughput assays
(TaqMan, Sequenom, Illumina GoldenGate on the
BeadXpress), or a combination thereof. Quality control
was implemented at each study site independently. Only
SNPs with high call rates (>95%) were included in the
analyses. In addition, all PAGE study sites genotyped
360 DNA samples from the International HapMap Pro-
ject for concordance analysis.
Statistical methods
Cohort-specific analyses
Statistical analyses were performed separately by each
cohort following the same analysis plan. Within each ra-
cial/ethnic group and sex stratum, linear regression was
used to evaluate the association of each SNP with HDL-
C, LDL-C, or natural log-transformed TG levels, assum-
ing an additive genetic model. Models were adjusted for
age and field center (for multi-center studies). Previous
PAGE study results for lipids demonstrated that further
adjustment for body mass index, current smoking, type
2 diabetes, post-menopausal status, current hormone
use, myocardial infarction, and ancestry using principal
components, did not meaningfully impact the associ-
ation of these SNPs with lipid levels [46]. Analyses were
performed without regard to lipid lowering medication
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reported such medication use, and their inclusion did
not appreciably alter results in previous PAGE lipids
work [46].Meta-analyses
Sex-specific beta coefficients were combined within each
racial/ethnic group using an inverse variance-weighted
fixed-effects meta-analysis, using METAL software [47].
For each SNP, significance of association within each
stratum was evaluated using a 1-df Chi-square test. Het-
erogeneity of effects between the sexes was then evalu-
ated using the following 1-df Chi-square test: (βm-βf )/
(SEm
2 + SEf
2) ~ χ21, where βm and βf represent the meta-
analyzed effect estimates among males and females, re-
spectively. In addition, for each SNP, sex-differentiated
tests of association were performed using a Chi-square
test (2 df) as described by Magi et al. [48] in which the
1-df Chi-square statistics for the SNP-phenotype associ-
ations for males and females are summed. This method
yields a single P-value of association but permits the ef-
fect estimates for males and females to differ. It also per-
mits inclusion of single-sex studies such as WHI that
otherwise would not be able to contribute to a trad-
itional interaction meta-analysis. Reported P-values were
not adjusted for multiple testing.
Reported P-values include Pcomb, the genotype-
phenotype association p-value not allowing for a
sex-specific association; Pdiff, the genotype-phenotype as-
sociation P-value allowing for different effects by sex;
and Phet, the P-value for heterogeneity of sex effects.
The a priori criterion for heterogeneity was set at Phet <
0.001 (a Bonferroni correction for the number of SNPs
examined; 0.05/49).Sample size and power calculations
Sample size and power for gene-environment interac-
tions were calculated using Quanto software (http://
hydra.usc.edu/gxe/). To calculate sample sizes required
to replicate previous findings, we used the following as-
sumptions: power = 80%; alpha = 0.05 (two-sided); inter-
action effect size = (male effect – female effect, in
standard deviation units); minor allele frequency = the
minor allele frequency in the PAGE population; additive
genetic model. To calculate minimum detectable effect
sizes, we set sample size equal to the PAGE sample size
but kept the other assumptions. Because none of the
other racial/ethnic groups in PAGE had adequate power
to detect gene-environment interactions, only the
European-American results are presented in the main
text. Results for the other groups are presented in the
supplementary materials.Additional file
Additional file 1: This file contains Supplementary Tables 1-4 and
Supplementary Figure 1 as described in the text.
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